

Supplementary Table 1. Clinicopathological characteristics and survival of the patients with Crohn disease (CD)-associated colorectal adenocarcinoma according to histologic type

Characteristic	Favorable	Unfavorable	P-value
No. of patients	6	11	
Sex, female:male	4 (66.7):2 (33.3)	3 (27.3):8 (72.7)	0.16
Age (yr)			
At operation	35 ± 10.7 (27-42)	42.27 ± 10.56 (32-53)	0.37
At diagnosis	27.33 ± 8.5 (21-34)	31.73 ± 8.5 (25-39)	0.15
Location			0.99
Colon	1 (16.7)	1 (9.1)	
Rectum	5 (83.3)	10 (90.9)	
History of perianal fistula	5 (83.3)	8 (72.7)	0.99
Tumor associated with perianal fistula	3 (50.0)	7 (63.6)	0.64
Duration of disease (yr)			
≥ 5	5 (83.3)	10 (90.9)	0.99
≥ 10	3 (50.0)	8 (72.7)	0.6
Preoperative CD medication			
Anti-TNF-α only	0 (0)	1 (9.1)	0.64
Immunomodulator only	3 (50.0)	4 (36.4)	0.99
Combination	1 (16.7)	2 (18.2)	0.99
Differentiation or tumor type			
WD/MD	6 (100)		
PD/mucinous/SRC		3(17.3)/ 5(45.5)/ 3(27.3)	
Operation name			0.53
APR	3 (50.0)	5 (45.5)	
TC or TPC with stomy	1 (16.7)	2 (18.2)	
Stoma with biopsy		3 (27.3)	
RHC/uLAR with CAA	2 (33.3)	1 (9.1)	
Pathologic stage			0.025*
pCR	1 (16.7)		
I	3 (50.0)		
II	2 (33.3)	4 (36.4)	
III		1 (9.1)	
IV		6 (54.4)	
Additional treatment			0.13
None	3 (50.0)	0 (0)	
Best supportive care		1 (9.1)	
Neoadjuvant CCRT	1 (16.7)	2 (18.2)	
Adjuvant CTx	2 (33.3)	1 (9.1)	
Adjuvant CCRT		2 (18.2)	
Palliative CTx		3 (27.3)	
Palliative CCRT		2 (18.2)	
Survival			0.13
Yes	1 (16.7)	7 (63.6)	
No	5 (83.3)	4 (36.4)	

Values are presented as number only, number (%), means ± standard deviation (interquartile range).

NEC, neuroendocrine carcinoma; anti-TNF-α, anti-tumor necrosis factor α; WD, well-differentiated; MD, moderately-differentiated; PD, poorly-differentiated; SRC, signet-ring cell carcinoma; APR, abdominoperineal resection; TC, total colectomy; TPC, total proctocolectomy; RHC, right hemicolectomy; uLAR, ultra-low anterior resection; CAA, coloanal anastomosis; pCR, pathologic complete remission; CCRT, chemoradiotherapy; CTx, chemotherapy.

*P < 0.05.